Biomarkers May Predict Response to BRAF and MEK inhibitors in Malignant Melanoma – OncoPrescribe
Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway | Personalized Medicine in Oncology
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma | Oncogene
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review - ScienceDirect
Clinical Development of BRAF plus MEK Inhibitor Combinations: Trends in Cancer
Figure 1 from Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. | Semantic Scholar
Mechanisms of intrinsic resistance to BRAF-MEK inhibitors. Coexistent... | Download Scientific Diagram
Frontiers | Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
BRAF/MEK Inhibitor Combinations Impressive in Melanoma Trials - The ASCO Post
BRAF inhibitors
IJMS | Free Full-Text | Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
Targeting BRAF Mutation Positive Cancers: Melanoma, Lung and Colorectal | Roswell Park Comprehensive Cancer Center - Buffalo, NY
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma - Lim - 2017 - Cancer - Wiley Online Library
![PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c096f23cc88dea1f4635eb820fb4548ab1056b0f/4-Figure1-1.png "PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar")
PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial - The Lancet Oncology
MEK inhibitors for the treatment of non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
Cancers | Free Full-Text | Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Cancers | Free Full-Text | Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors - Muñoz-Couselo - Annals of Translational Medicine
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? - ScienceDirect
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management - Livingstone - Chinese Clinical Oncology
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma | Nature Reviews Clinical Oncology
BRAF/MEK inhibition
